{
  "documentMetadata": {
    "title": "Portal Vein Suppurative (Septic) Thrombophlebitis",
    "lastUpdated": "2023-10-26",
    "sourceFile": "Portal Vein Suppurative (Septic) Thrombophlebitis.pdf"
  },
  "content": [
    {
      "type": "header",
      "level": 1,
      "text": "Clinical Setting"
    },
    {
      "type": "list",
      "items": [
        "Person with an intra-abdominal infection (e.g., appendicitis, diverticulitis) develops suppurative phlebitis of the portal vein. Also referred to as pylephlebitis.",
        "Most common in setting of pancreatitis and diverticulitis.",
        "Etiology linked to the bowel flora: Enterobacteriaceae (now Enterobacterales), anaerobic gram negative bacilli (Bacteroides sp.), Clostridia sp., GpB Streptococci, viridans streptococci and more.",
        "Phlebitis may be complicated by suppurative liver abscess(es) and/or bacteremia (44% in one case series): J Gastrointest. Surg 2016;20:656",
        "For images, see N Engl J Med 373:2270, 2015 and J Emerg Med 2016;50:e147"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Diagnosis"
    },
    {
      "type": "list",
      "items": [
        "Suspect with intra-abdominal infectious process. Confirm by CT scan.",
        "Collect blood cultures (positive blood cultures in 23-88%",
        "Imaging with CT scans and/or ultrasound"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Etiologies"
    },
    {
      "type": "list",
      "items": [
        "Enterobacteriaceae (Enterobacterales): e.g., E. coli, Klebsiella sp.",
        "Streptococci (Grp B)",
        "Bacteroides fragilis",
        "Clostridium perfringens"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Primary Regimens"
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Empiric Therapy"
        },
        {
          "type": "list",
          "items": [
            "Draw blood cultures"
          ]
        },
        {
          "type": "nestedContent",
          "content": [
            {
              "type": "paragraph",
              "text": "If low prevalence of multi-drug resistant gram negative bacilli (MDR GNB):"
            },
            {
              "type": "regimen",
              "regimenData": {
                "intent": "treatment",
                "components": [
                  {
                    "drug": "Piperacillin-tazobactam",
                    "dose": "3.375 gm",
                    "route": "IV",
                    "frequency": "over 30 minutes then, 4 hrs later, start 3.375 gm IV infused over 4hrs and repeat q8h"
                  }
                ]
              }
            },
            {
              "type": "regimen",
              "regimenData": {
                "intent": "treatment",
                "condition": "Penicillin allergy",
                "components": [
                  {
                    "drug": "Ciprofloxacin",
                    "dose": "400 mg",
                    "route": "IV",
                    "frequency": "q12h"
                  },
                  {
                    "drug": "Metronidazole",
                    "dose": "500 mg",
                    "route": "IV",
                    "frequency": "q8h",
                    "connector": "+"
                  }
                ]
              }
            },
            {
              "type": "list",
              "items": [
                "If high prevalence of MDR GNB, specific therapy directed by blood culture results"
              ]
            }
          ]
        }
      ]
    },
    {
      "type": "nestedContent",
      "content": [
        {
          "type": "paragraph",
          "text": "Directed/Specific Therapy"
        },
        {
          "type": "regimen",
          "regimenData": {
            "intent": "treatment",
            "condition": "High prevalence of MDR GNB or suspected/identified ESBLs",
            "components": [
              {
                "drug": "Meropenem",
                "dose": "1-2 gm",
                "route": "IV",
                "frequency": "q8h"
              }
            ]
          }
        },
        {
          "type": "nestedContent",
          "content": [
            {
              "type": "paragraph",
              "text": "High prevalence of KPC carbapenemase-producing GNB:"
            },
            {
              "type": "list",
              "items": [
                "Often susceptible in vitro to:"
              ]
            },
            {
              "type": "regimen",
              "regimenData": {
                "intent": "treatment",
                "components": [
                  {
                    "drug": "Meropenem-vaborbactam",
                    "dose": "4 gm",
                    "route": "IV",
                    "frequency": "over 3 hr and repeat q8h"
                  }
                ]
              }
            },
            {
              "type": "regimen",
              "regimenData": {
                "intent": "treatment",
                "components": [
                  {
                    "drug": "Ceftazidime-avibactam",
                    "dose": "2.5 gm",
                    "route": "IV",
                    "frequency": "over 3 hr"
                  }
                ]
              }
            },
            {
              "type": "regimen",
              "regimenData": {
                "intent": "treatment",
                "components": [
                  {
                    "drug": "Imipenem-cilastatin-relebactam",
                    "dose": "1.25 gm",
                    "route": "IV",
                    "frequency": "q6h over 30 min"
                  }
                ]
              }
            }
          ]
        },
        {
          "type": "list",
          "items": [
            "Metallocarbapenemase producing MDR GNB: see Antimicrobial Stewardship and Alternative therapy"
          ]
        }
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Alternative Regimens"
    },
    {
      "type": "list",
      "items": [
        "Can consider salvage therapy with:"
      ]
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Aztreonam",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "over 3hr q8h"
          },
          {
            "drug": "Ceftazidime-avibactam",
            "dose": "2.5 gm",
            "route": "IV",
            "frequency": "over 3 hr",
            "connector": "+"
          }
        ],
        "notes": "with concomitant (separate IV lines)"
      }
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Cefiderocol",
            "dose": "2 gm",
            "route": "IV",
            "frequency": "q8h infused over 3 hr"
          }
        ]
      }
    },
    {
      "type": "regimen",
      "regimenData": {
        "intent": "treatment",
        "components": [
          {
            "drug": "Eravacycline",
            "dose": "1 mg/kg",
            "route": "IV",
            "frequency": "q12h"
          }
        ]
      }
    },
    {
      "type": "header",
      "level": 1,
      "text": "Antimicrobial Stewardship"
    },
    {
      "type": "list",
      "items": [
        "Antimicrobial drug selection considerations:",
        "For metallo-carbapenemase, there is no gold standard therapy.",
        "Combinations of a polymyxin + meropenem, tigecycline, and rifampin have failed.",
        "Case report of success with combination of Aztreonam + Ceftazidime-avibactam for bacteremia Morganella infection (Antimicrob Agents Chemother 2019;63:e02463-18)"
      ]
    },
    {
      "type": "header",
      "level": 1,
      "text": "Comments"
    },
    {
      "type": "list",
      "items": [
        "No indication for anticoagulant therapy",
        "No indication for surgical drainage"
      ]
    }
  ]
}
